Abstract
| Lingua originale | English |
|---|---|
| Numero di pagine | 11 |
| Rivista | Cancers |
| Volume | 11 |
| Stato di pubblicazione | Published - 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cita questo
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. / Barraco, Nadia; Curro', Giuseppe; Badalamenti, Giuseppe; Incorvaia, Lorena; Guarini, Aurelia Ada; Galvano, Antonio; Bazan, Viviana; Calo', Valentina; Russo, Antonio; Silvestris, Nicola; Beretta, Giordano Domenico; Castellana, Luisa; Rizzo, Sergio; Cutaia, Sofia; Cusenza, Stefania.
In: Cancers, Vol. 11, 2019.Risultato della ricerca: Article
}
TY - JOUR
T1 - How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
AU - Barraco, Nadia
AU - Curro', Giuseppe
AU - Badalamenti, Giuseppe
AU - Incorvaia, Lorena
AU - Guarini, Aurelia Ada
AU - Galvano, Antonio
AU - Bazan, Viviana
AU - Calo', Valentina
AU - Russo, Antonio
AU - Silvestris, Nicola
AU - Beretta, Giordano Domenico
AU - Castellana, Luisa
AU - Rizzo, Sergio
AU - Cutaia, Sofia
AU - Cusenza, Stefania
PY - 2019
Y1 - 2019
N2 - Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). The right sequence of the treatments in all RAS (KRAS/NRAS) wild type (wt) patients has not precisely defined. We evaluated the impact of aforementioned targeted therapies in second line setting, analyzing efficacy and safety data from phase III clinical trials. We performed both direct and indirect comparisons between anti-EGFR and anti-VEGF. Outcomes included disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and G3-G5 toxicities. Our results showed significantly improved OS (HR 0.83, 95% CI 0.72-0.94) and DCR (HR 1.27, 95% CI 1.04-1.54) favouring anti-VEGF combinations in overall population; no statistically significant differences in all RAS wt patients was observed (HR 0.87, 95% CI 0.70-1.09). Anti-EGFR combinations significantly increased ORR in all patients (RR 0.54, 95% CI 0.31-0.96), showing a trend also in all RAS wt patients (RR 0.63, 95% CI 0.48-0.83). No significant difference in PFS and DCR all RAS was registered. Our results provided for the first time a strong rationale to manage both targeted agents in second line setting.
AB - Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). The right sequence of the treatments in all RAS (KRAS/NRAS) wild type (wt) patients has not precisely defined. We evaluated the impact of aforementioned targeted therapies in second line setting, analyzing efficacy and safety data from phase III clinical trials. We performed both direct and indirect comparisons between anti-EGFR and anti-VEGF. Outcomes included disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and G3-G5 toxicities. Our results showed significantly improved OS (HR 0.83, 95% CI 0.72-0.94) and DCR (HR 1.27, 95% CI 1.04-1.54) favouring anti-VEGF combinations in overall population; no statistically significant differences in all RAS wt patients was observed (HR 0.87, 95% CI 0.70-1.09). Anti-EGFR combinations significantly increased ORR in all patients (RR 0.54, 95% CI 0.31-0.96), showing a trend also in all RAS wt patients (RR 0.63, 95% CI 0.48-0.83). No significant difference in PFS and DCR all RAS was registered. Our results provided for the first time a strong rationale to manage both targeted agents in second line setting.
UR - http://hdl.handle.net/10447/367369
M3 - Article
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
ER -